SCHEMBL287142

SCHEMBL287142

COC(=O)C(C)(C)[C@](C)(N[S+]([O-])C(C)(C)C)c1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.41
ALDH1A1 P00352 4/20 0.41
GAA P10253 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
THRB P10828 1/20 0.41
CYP2C19 P33261 1/20 0.40
POLB P06746 4/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 5/20 0.37
KMT2A Q03164 4/20 0.37
HIF1A Q16665 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
LMNA P02545 4/20 0.35
MEN1 O00255 3/20 0.35
PKM P14618 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL287143 1.00 HTT (0.41) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL287144 1.00 HTT (0.41) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL4074382 0.84 ALDH1A1 (0.42) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL569019 0.83 PTGDR2 (0.32) ALDH1A1L3MBTL1KMT2ALMNA
SCHEMBL10295522 0.82 ALDH1A1 (0.42) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL1976991 0.82 ALDH1A1 (0.42) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL1976994 0.82 ALDH1A1 (0.42) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL1976993 0.82 ALDH1A1 (0.42) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL4083097 0.81 ALDH1A1 (0.41) HTTALDH1A1GAAL3MBTL1THRB
SCHEMBL1976718 0.81 ALDH1A1 (0.41) HTTALDH1A1GAAL3MBTL1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-13 US disclosed
US-8815881-B2 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-08-26 US disclosed
EP-2603496-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2013-06-19 EP disclosed
US-8461160-B2 Dihydropyrimidinones HOFFMANN-LA ROCHE, INC. (US) 2013-06-11 US disclosed
EP-2427437-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2012019966-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-02-16 WO disclosed
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) 2012-02-09 US disclosed
WO-2010128058-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286158-A1 DIHYDROPYRIMIDINONES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 HTT 623/4885ALDH1A1 326/4885GAA 28/4885
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 HTT 623/4885ALDH1A1 326/4885GAA 28/4885
US-20100286158-A1 DIHYDROPYRIMIDINONES BACE2, BACE1, PSEN2 HTT 1741/4885ALDH1A1 563/4885GAA 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.